Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Bempedoic acid cuts LDL by 15% in patients with high levels despite maximal treatment

Key clinical point: Bempedoic acid improved LDL cholesterol in patients who had high levels despite maximal statin use.

Major finding: The prodrug reduced LDL cholesterol levels by 15%, compared with a 2.4% increase in the placebo group.

Study details: CLEAR Wisdom, a 52-week placebo-controlled study in 2,300 patients.

Disclosures: This study was funded by Esperion Therapeutics. Dr Goldberg reported receiving research grants/support from Amgen, Amarin, Pfizer, Regeneron, Sanofi, IONIS, Novartis, and Merck and serving as a consultant for Esperion, Novartis, Akcea, OptumRX, 23andMe, Sanofi/Regeneron, and Merck.

Citation:

Goldberg AC et al. JAMA. 2019 Nov 12;322:1780-8.